 _____________________________________________________________________________________________  
1 of 49 
 Clinical Validation of a Molecular Test for Ciprofloxacin -
Susceptibility in Neisseria gonorrhoeae  
 
DMID Protocol Number:  15-0090 
 
DMID Funding Mechanism:  
Contract  Number: HHSN272201300014I  
Task Order Number: HHSN27200006  
 
 
Sponsor:   
Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases 
National Institutes of Health 
  
Principal Investigator: Jeffrey D. Klausner, MD, MPH   
  
DMID Clinical Project Manager: Peter Wolff, MHA  
  
Version Number: 7.0  
 
Date: 17 December 2018  
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
2 of 49 
 STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by the following:  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 8 12) 
• International Conference on Harmonisation: Good Clinical Practice (ICH) E6; 62 Federal 
Register 25691 (1997); and future revisions  
• NIH Clinical Terms of Award 
The study is a nonsignificant risk device study and must comply with the abbreviated Investigational Device Exemption (IDE) requirements  under 21 CFR  §812.2 (b) . 
All key personnel (all individuals responsible for the design and conduct of this study) have completed Human Subjects Protections Training. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
3 of 49 
 SIGNATURE PAGE 
The signature below constitutes the approval of this protocol and the attachments, and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Site Investigator:  
 
Signed:   Date:   
 Name  
Title 
   
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
4 of 49 
 TABLE OF CONTENTS  
Page 
Statement of Compliance .............................................................................................................. 2  
Signature Page ............................................................................................................................. 3  
List of Abbreviations  ...................................................................................................................... 7  
Protocol Summary  ........................................................................................................................ 8  
1 Key Roles  ........................................................................................................................... 10 
2 Background Information and Scientific Rationale  .............................................................. 11 
2.1 Background Information ......................................................................................... 11 
2.2 Rationale ................................................................................................................ 11 
2.3 Potential Risks and Benefits  ................................................................................... 12 
2.3.1 Potential Risks  ............................................................................................ 12 
2.3.2 Known Potential Benefits  ............................................................................ 13 
3 Objectives  .......................................................................................................................... 15 
3.1 Study Objectives  .................................................................................................... 15 
3.1.1 Primary Objective ....................................................................................... 15 
3.1.2 Secondary Objectives  ................................................................................. 15 
3.1.3 Exploratory Objectives  ................................................................................ 15 
3.2 Study Outcome Measures  ...................................................................................... 15 
3.2.1 Primary Outcome Measure ......................................................................... 15 
3.2.2 Secondary Outcome Measures  .................................................................. 15 
3.2.3 Exploratory Outcome Measures  ................................................................. 15 
4 Study Design ...................................................................................................................... 17 
5 Study Enrollment and Withdrawal  ...................................................................................... 18 
5.1 Subject Inclusion Criteria ........................................................................................ 18 
5.2 Subject Exclusion Criteria ...................................................................................... 19 
5.3 Subject Withdrawal  ................................................................................................. 19 
5.3.1 R easons for Withdrawal  ............................................................................. 19 
5.3.2 Handling of Withdrawals ............................................................................. 20 
6 GYRASE A ASSAY/study treatment  .................................................................................. 21 
6.1 Gyrase A Assay Description ................................................................................... 21 
6.2 Ciprofloxacin Description ........................................................................................ 21 
6.2.1 Ciprofloxacin Formulation ........................................................................... 21 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
5 of 49 
 6.2.2 Ciprofloxacin Acquisition ............................................................................ 22 
6.2.3 Storage and Stability  .................................................................................. 22 
6.2.4 Dosage Preparation and Administration ..................................................... 22 
6.2.5 Accountability Procedures  .......................................................................... 22 
6.2.6 Assessment of Subject Compliance ........................................................... 22 
6.2.7 Concomitant Medications  ........................................................................... 22 
7 Study Schedule .................................................................................................................. 24 
7.1 Visit 1, Day 1 (Screening/Enrollment)  .................................................................... 24 
7.2 Visit 2, Day 5-10  (Test of Cure Visit)  ..................................................................... 25 
7.3 Visit 3, Day 11 to 14 (Test of Cure Results)  ........................................................... 26 
7.4 Unscheduled/Early Termination Visit ..................................................................... 26 
8 Study Procedures/Evaluations  ........................................................................................... 27 
8.1 Clinical Evaluations  ................................................................................................ 27 
8.2 Laboratory Evaluations  ........................................................................................... 28 
8.2.1 Clinical Laboratory Evaluations  .................................................................. 28 
8.2.2 Special Assays or Procedures for Enrolled Subjects.................................. 28 
8.2.3 Specimen Preparation, Handling, and Shipping  ......................................... 29 
9 Assessment of Safety  ........................................................................................................ 31 
10 Clinical Monitoring .............................................................................................................. 32 
10.1 Site Monitoring Plan ............................................................................................... 32 
11 Statistical Considerations  ................................................................................................... 33 
11.1 Study Hypotheses  .................................................................................................. 33 
11.2 Sample Size Considerations .................................................................................. 33 
11.3 Planned Analyses  ................................................................................................... 35 
11.3.1 Planned Futility Review  .............................................................................. 35 
11.4 Final Analysis Plan  ................................................................................................. 35 
11.4
.1 Analysis Populations  .................................................................................. 35 
11.4.2 Baseline Characteristics  ............................................................................. 36 
11.4.3 Efficacy and Other Analysis Plan  ............................................................... 36 
12 Source Documents and Access to Source Data/Documents  ............................................. 39 
13 Quality Control and Quality Assurance .............................................................................. 40 
14 Ethics/Protection of Human Subjects  ................................................................................. 41 
14.1 Ethical Standard ..................................................................................................... 41 
14.2 Institutional Review Board ...................................................................................... 41 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
6 of 49 
 14.3 Informed Consent Process  ..................................................................................... 41 
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  .................... 42 
14.5 Subject Confidentiality  ............................................................................................ 42 
14.6 Study Discontinuation  ............................................................................................. 43 
14.7 Future Use of Stored Specimens  ........................................................................... 43 
15 Data Handling and Record Keeping .................................................................................. 44 
15.1 Data Management Responsibilities ........................................................................ 44 
15.2 Data Capture Methods  ........................................................................................... 44 
15.3 Types of Data ......................................................................................................... 44 
15.4 Timing/Reports  ....................................................................................................... 45 
15.5 Study Records Retention ....................................................................................... 45 
15.6 Protocol Deviations  ................................................................................................ 45 
16 Publication Policy  ............................................................................................................... 46 
17 Literature References  ........................................................................................................ 47 
Appendix A: Schedule of Events  ................................................................................................. 49 
 
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
7 of 49 
 LIST OF ABBREVIATIONS 
BV Bacterial Vaginosis  
CDC  Centers for Disease Control and Prevention 
CFR Code of Federal Regulations 
CRF Case Report Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH,  
 DHHS  
DNA  Deoxyribonucleic Acid 
eCRF  Electronic Case Report Form  
gyrA Gyrase A Genotype 
ICH International Council for Harmonisation 
ICMJE  International Committee of Medical Journal Editors  
IEC Independent or Institutional Ethics Committee  
IRB Institutional Review Board 
ITT Intent-to-Treat 
MIC Minimum Inhibitory Concentration  
micro -ITT Microbiological Intent-to- Treat 
NAAT Nucleic Acid Amplification Tes t 
NIAID National Institute of Allergy and Infectious Diseases, NIH, DHHS  
NIH National Institutes of Health 
OHRP  Office for Human Research Protections  
PCR  Polymerase Chain Reaction 
PP Per-Protocol  
QA Quality Assurance 
QC Quality Control  
SDCC  Statistical Data and Coordinating Center  
SOP  Standard Operating Procedure 
STD Sexually Transmitted Disease 
  
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
8 of 49 
 PROTOCOL SUMMARY  
Title:  Clinical Validation of a Molecular Test for Ciprofloxacin -
Susceptibility in Neisseria gonorrhoeae 
 
Population:  Approximately 381 subjects will be enroll ed to identify  
approximately 257 per protocol eligible subjects diagnosed with 
untreated ser ine 91 gyrase A genotype Neisseria gonorrhoeae 
of the rectum, or male or female urogenital tract   
 
Number of Sites:  Up to eight sites in the United States  
 
Study Duration:  Approximately 30 months after enrollment of the first subject  
 
Subject Participation Duration:  11-14 days per subject  
 
Description of Agent or Intervention:  Directly  observed treatment with a single dose of ciprofloxacin  
500 mg orally for Neisseria gonorrhoeae infections deemed 
serine 91 gyrase A genotype by real -time polymerase chain 
reaction with fluorescent hybridization probe detection of 
sequence  
 
Objectives : Primary:  
To determine the efficacy of ciprofloxacin for treatment of uncomplicated Neisseria  gonorrhoeae infections with gyrA 
serine 91 genotype 
 Secondary: 
To investigate efficacy of ciprofloxacin for treatment of 
uncomplicated serine 91 gyrase A genotype Neisseria 
gonorrhoeae  infection by anatomic site  
To determine the sensitivity of the gyrase A assay for detection 
of ciprofloxacin-susceptible Neisseria gonorrhoeae infections  
 
Description of Study Design:  See Schematic  
 
Estimated Time to Complete 
Enrollment:  Approximately 24 months  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
9 of 49 
 Schematic  
 
                       Prior to enrollment, screen subjects for eligibility  
(N. gonorrhoeae  positive and untreated and gyrA  serine  91 positive)  
 
 Visit 1, Day 1 (Enrollment)  
Obtain Informed Consent  
Collect specimen for N. gonorrhoeae  culture, N. gonorrhoeae  NAAT, and gyrA  serine 91 
genotype from all suspected N. gonorrhoeae positive anatomic sites (throat, rectum, or male 
or female urogenital tract)  
Administer directly observed single dose of c iprofloxacin 500 mg PO  
  
Collect specimens for N. gonorrhoeae culture, N. gonorrhoeae NAAT, and gyrA  serine 91 
genotype from all anatomic sites swabbed at Visit 1, Day  
 
Test results provided by phone  
  N. gonorrhoeae  negative 
or  
treated or  
gyrA  serine  91  negative  
 N. gonorrhoeae  
positive and  
untreated and  
gyrA serine  91 positive 
 
 
 Visit 2, Day 5 -10 (Test of Cure)  
 Visit 3, Day 11 -14 (Test of Cure Results)  
Test of Cure Negative  
Culture -/NAAT - 
 Test of Cure Positive  
Culture -/NAAT+  
Culture+/NAAT+  
Culture+/NAAT - 
 
 
Off Study  
 Off Study  
Refer for standard of care  
treatment for N. 
gonorrhoeae  
  
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
10 of 49  
 1 KEY ROLES 
Principal Investigator  Jeffrey D. Klausner, MD, MPH  
Principal Investigator, STAR STI CTG  
Professor of Medicine and Public Health 
Division of Infectious Diseases  
David Geffen School of Medicine and Jonathan 
and Karin Fielding School of Public Health University of California, Los Angeles  
Los Angeles, CA 90095-1772 
Phone: XXXXXXXXXX 
Email: XXXXXXXXXX 
Co-Investigator  Sheldon Morris, MD, MPH  
Antiviral Research Center  University of California, San Diego  220 Dickinson Street, Suite A
 
San Diego, CA 92103 Phone: XXXXXXXXXX 
Email: XXXXXXXXXX  
 
Contact information for site investigators and key staff at DMID, the coordinating center, and the 
SDCC is located in the Manual of Procedures.  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
11 of 49  
 2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
2.1 Background Information 
Gonorrhea is the second most commonly reported notifiable disease in the United States 
with more than 330,000 cases reported in 2012, a rate of 107.5 per 100,000 population 
[1]. Over the past 75 years, Neisseria gonorrhoeae (N. gonorrhoeae)  infections have 
become increasingly resistant to antimicrobial therapy , first to sulfa-based antibiotics, 
then penicillins, tetracyclines, fluoroquinolones, and now extended-spectrum 
cephalosporins [2 ]. Prior to the advent of ciprofloxacin-resistant N. gonorrhoeae, 
ciprofloxacin was the primary first-line recommended therapy for N. gonorrhoeae 
infections of the throat, rectum, urethra, and cervix. From 1998 to 2006, c iprofloxacin 
was the Centers for Disease Control and Prevention (C DC) recommended treatment for 
N. gonorrhoeae in all anatomic sites . Prior to widespread ciprofloxacin resistance , the 
efficacy of ciprofloxacin treatment in susceptible N. gonorrhoeae infections was 
estimated at more than 99%  [3-4]. In 2007, due to high rates of ciprofloxacin resistance 
in N. gonorrhoeae nationally , the CDC recommended the discontinuation of ciprofloxacin 
treatment for gonorrhea, which was followed by a decline in ciprofloxacin N. 
gonorrhoeae resistance nationally [ 5]. At this time, the only recommended treatment for 
N. gonorrhoeae infection is dual antibiotic therapy with injectable ceftriaxone and oral 
azithromycin or doxycycline [6 ]. 
 For decades , bacterial culture was the standard diagnostic modality for N. gonorrhoeae 
infections. Culture is specific, but studies have demonstrated that the molecular -based 
enzyme immunoassay or nucleic acid amplification test (NAAT) has a higher clinical 
sensitivity than culture [7] . However, there has not been a widely used and reliable 
technology that allows for antibiotic susceptibility testing from non-culture specimens .  
 It has been recently demonstrated that N. gonorrhoeae-d eoxyribonucleic acid (DNA) 
mutations can be detected using modern molecular techniques and real -time 
polymerase chain reaction (PCR)  assays can be used to detect reproducible , clinically 
significant resistance [8-10]. A protocol for the detection of alterations in the gyrase A 
gene (gyrA),  the target of ciprofloxacin anti -gonococcal activity , has been validated [8 ]. 
While molecular markers of susceptibility have high concordance, sensitivity and a specificity of 93% and 100%, respectively, compared with standard antimicrobial susceptibility testing, the clinical performance of the test and the response to therapy 
based on a molecular susceptibility result in N. gonorrhoeae is unknown. 
2.2 Rationale 
Resistance to extended-spectrum cephalosporins was first identified in Japan and is 
increasing in the western United States and among men who have sex with men [11]. 
Antimicrobial resistance mechanisms have been fairly well  described as mutations in 
target proteins, alterations in cell wall components , or increases in efflux pumps [2 ].  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
12 of 49  
  
Currently, the nationwide frequency of N. gonorrhoeae isolates with decreased 
ciprofloxacin susceptibility, minimum inhibitory concentration (MIC) ≥ 0.125 μg/mL, or 
resistance (MIC ≥ 0.5 μg/mL) is relatively modest at 13.5%  [12]. Prior experience with 
changing antibiotic treatment guidelines has demonstrated that major shifts in antibiotic 
use may modify the ecology of drug resistance. For example, restricting erythromycin use in G roup A streptococcal infections in Finland led to a population-level decrease in 
erythromycin-resistance in that organism [13 ].  
 While molecular methods to diagnose N. gonorrhoeae h ave greatly improved the 
detection of infection [14 ], they have historically precluded the ability to perform antibiotic 
susceptibility testing. Although regional surveillance data critically inform treatment 
recommendations, those data cannot be used for real -time individualized clinical 
management. The clinical validation of an assay to determine the ciprofloxacin 
susceptibility of N. gonorrhoeae infec tions could result in increased use of ciprofloxacin 
for ciprofloxacin-susceptible N. gonorrhoeae infections and resultant decreased use of 
extended-spectrum cephalosporins, thereby reducing the selection pressure for 
cephalosporin resistance in N. gonorrhoeae. An immediate benefit to taking ciprofloxacin 
would be for those with cephalosporin allergies who would have to take combination therapy that is more difficult to administer.  
2.3 Potential Risks and Benefits 
2.3.1 Potential Risks 
Performance of the assay  
Clinical specimens will be tested for  a molecular marker of ciprofloxac in 
susceptibility . Treatment decisions will be made by the subject’s clinician, per 
standard protocols, based on interpretation of laboratory results and selection of the best course of treatment based on available information. There is a small risk 
of a misclassification of susceptibility if the test were to show that the N. gonorrhoeae infection is ciprofloxacin-susceptible  when in fact, it is resistant, and 
a subject with ciprofloxacin-resistant N. gonorrhoeae infection would not receive 
the appropriate treatment. The risk would be ameliorated if the test of cure visit (Visit 2, Day  5-10) displayed a treatment failure and the subject received 
standard treatment. The risk would therefore be that this would result in a delay 
of effective treatment.   
The risk of a N. gonorrhoeae false negative test of cure result is estimated to be 
less than 0.5% and would result in inappropriate treatment for a subject with 
ciprofloxacin -resistant N. gonorrhoeae infection [9]. The risks of treatment failure 
include continued symptoms and potential transmission of N. gonorrhoeae to 
partners. Without effective re-treatment, treatment failure might result in 
complications including pelvic inflammatory disease, ectopic pregnancy, 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
13 of 49  
 infertility, chronic pelvic pain, and increased risk of transmission and HIV 
infection.  
 
Risks from study procedures  
Subjects may become embarrassed, worried, or anxious when discussing their 
sexual practices or ways for protecting against HIV and other infections passed during sex. They may also experience anxiety while they await test results. 
Women may expect to feel a little discomfort during the speculum exam . 
Subjects may experience gagging, discomfort, fainting, or bleeding when swabs 
are collected from the throat, rectum, urethra or cervix. 
 
Risks of c iprofloxacin 
Ciprofloxacin may cause dizziness, nervousness, difficulty sleeping, or increased sensitivity to  sunlight, possibly resulting in sunburn. Like many antibiotics used to 
treat infections, ciprofloxacin may cause nausea, vomiting, stomach pain, 
headaches, tiredness, pale skin or a mild skin rash. Less often, hearing loss, kidney, liver or nerve problems, tendon pain, an irregular heartbeat, or fainting may occur. It is not known if ciprofloxacin will harm a fetus . Pregnancy tests can 
miss the first 14 days of pregnancy ; therefore, fetuses may be exposed to 
ciprofloxacin if a subject’s pregnancy is undetected at enrollment.  
Significant side effects of ciprofloxacin 
Significant side effects are rare, estimated to be less than 2%, and may include 
severe skin rash; hives; itching; difficulty breathing or swallowing; swelling of the 
face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs; hoarseness; yellowing of the skin or eyes; and rapid, pounding, or irregular heartbeat. 
 
Unknown risks  
There may be unknown risks that cannot be foreseen.  
2.3.2 Known Potential Benefits 
There are no known benefits  to individual subjects . A potential benefit to future N. 
gonorrhoeae-susceptible infected individuals is treatment with a less invasive 
regimen (orally administered vs. intramuscular injection), which is less painful . 
Results from this study may help gonorrhea-infected individuals by reducing drug 
resistance as a result of the use of the most appropriate treatment, which is 
guided by pretreatment determination of ciproflo xacin -susceptible gonococcal 
infection.   
 
The study will  help to assess the potential impact of a strategy to address the 
critical problem of emerging drug resistance in N. gonorrhoeae. Specifically, the 
information gained from this study can be used to influence national sexually 
transmitted disease ( STD) treatment policies and, therefore, result in a marked 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
14 of 49  
 decrease in extended-spectrum cephalosporin-resistant N. gonorrhoeae 
infection, improving the availability of treatment options for individuals i nfected 
with N. gonorrhoeae. 
 
This study may provide an alternative regimen for the treatment of gonorrhea in cases of cephalosporin allergy or antimicrobial resistance to cephalosporins. It may also provide an oral regimen for settings in which injections are not feasible. 
In addition, it may provide a convenient and easy-to-administer patient-delivered therapy for the partners of index cases . 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
15 of 49  
 3 OBJECTIVES  
3.1 Study Objectives 
3.1.1 Primary Objective 
To determine the efficacy of ciprofloxacin for treatment of uncomplicated  N. 
gonorrhoeae infections with gyrA serine 91 genotype  
3.1.2 Secondary Objectives 
1) To investigate the efficacy of ciprofloxacin for treatment of uncomplicated 
serine 91 gyrA N. gonorrhoeae infection by anatomic site  
2) To determine the sensitivity of the gyrA assay for detection of 
ciprofloxacin -susceptible  N. gonorrhoeae infections  
3.1.3 Exploratory Objectives 1) To characterize N. gonorrhoeae isolates and non-gyrA gene-dependent 
mechanisms of ciprofloxacin resistance post-treatment of uncomplicated 
N. gonorrhoeae infection by anatomic site using traditional and molecular 
methods like genotyping and sequencing 
2) To investigate the efficacy of ciprofloxacin for treatment of uncomplicated serine 91 gyrA N. gonorrhoeae infections by demographic and clinical 
characteristics  
3.2 Study Outcome Measures  
3.2.1 Primary Outcome Measure 
The proportion of subjects infected with gyrA serine 91 genotype N. gonorrhoeae  
with microbiological cure at Visit 2 ( Day 5-10) 
3.2.2 Secondary Outcome Measures 
1) The proportion of subjects infected with gyrA serine 91 genotype N.  
gonorrhoeae with microbiological cure at each anatomic site (throat, rectum, 
male or female urogenital tract) at Visit 2 ( Day 5-10)  
2) The proportion of subjects infected with gyrA serine 91 genotype N. 
gonorrhoeae identified by gyrA gene PCR who have ciprofloxacin-susceptible 
N. gonorrhoeae as identified by culture-based antimicrobial susceptibility 
testing at Visit 1 (Day 1) 
3.2.3 Exploratory Outcome Measures 
1) Identification and characterization of non-gyrA gene-dependent mechanisms 
of ciprofloxacin resistance by genotyping and whole genome sequencing 
(e.g., Illumina) of nucleic acid isolated from uncured subjects at Visit 2 (D ay 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
16 of 49  
 5-10). Genotyping and s equencing may be performed on nucleic acid isolated 
from different anatomic sites.  
2) The proportion of subjects infected with gyrA serine 91 genotype N. 
gonorrhoeae with microbiological cure at Visit 2 (Day 5-10) by demographic 
and clinical characteristics  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
17 of 49  
 4 STUDY DESIGN 
This study is a multi -center, single-arm , open-label  clinical study to assess the efficacy of 
one dose of ciprofloxacin given orally  in subjects infected with  untreated gyrA serine 91 
genotype N. gonorrhoeae as determined by a real -time PCR assay . The study will enroll  
approximately 381 subjects  to obtain a per protocol eligible target of 257 subjects age 18 
years or older  regardless of gender identification  who are seeking care in STD clinics at 
partici pating sites in the United States . Subjects who have untreated gyrA  serine 91 
genotype N. gonorrhoeae of the rectum, or male or female urogenital tract identified by a 
positive culture or NAAT conducted at a prior visit w ill be offered enrollment in the study. 
Subjects not consenting to participate in the study will receive treatment per local 
standard of care. 
 
At enrollment, Visit 1  (Day 1), a brief physical exam and medical and sexual history will 
be done. Subjects will have samples collected for N. gonorrhoeae culture and N. 
gonorrhoeae NAAT (to include gyrA serine 91 genotype) from each infected anatomic 
site (throat, rectum, male or female urogenital  tract)  to verify infection status.  
 
Subjects with gyrA serine 91 genotype rectal or urogenital N. gonorrhoeae will receive 
one dose of directly  observed ciprofloxacin 500 mg. Subjects will be observed in the 
clinic for at least 5 minutes after receiving ciprofloxacin and will be instructed to return to 
the clinic or to contact the study site coordinator immediately if they vomit within 1 hour of receiving ciprofloxacin . Subjects who vomit within 1 hour of study drug administration 
should be retreated for N. gonorrhoeae infection with an alternative recommended 
regimen per local standard of care.  
 Subjects will return for clinical and laboratory assessments at Visit 2 (Day 5-10), test of 
cure visit. Subjects will have repeat samples collected for N. gonorrhoeae culture and N. 
gonorrhoeae NAAT from all anatomic sites swabbed at Visit 1  (Day 1 ).  
 
For Visit 3 (Day 11-14) , test results will be provided to subjects by phone call. No further 
follow -up is required for subjects who test culture negative and NAAT negative. Subjects 
who test culture positive or NAAT positive will be referred for standard of care treatment for N. gonorrhoeae. 
 The duration of the study for each subject will be approximately 11-14 days. Study 
enrollment is expected to be completed in 24 months.  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
18 of 49  
 5 STUDY ENROLLMENT AND  WITHDRAWAL  
5.1 Subject Inclusion Criteria  
Subjects must meet all of  the inclusion criteria in order to be eligible to participate in the 
study . Subjects who present with a new N. gonorrhoeae infection may be rescreened for 
eligibility. No exemptions are granted on Subject Inclusion/Exclusion Criteria in DMID -
sponsored studies.  
 
1. W illing and able to give voluntary written informed consent before any study related 
procedure is performed. 
2. 18 years or older  on the day of enrollment.  
3. Untreated gyrA serine 91 genotype N. gonorrhoeae of the rectum, or male or female 
urogenital tract*, as determined by the gyrA test assay on a specimen collected 
within 30 days of enrollment. 
*Subjects must have gyrA serine 91 genotype detected for N. gonorrhoeae from at 
least one non-pharynge al site.  
4. W illing to abstain from sexual intercourse or use condoms  during any sexual contact 
until the Test of Cure Visit (Visit 2, Day 5-10) is complete. 
5. Women of childbearing potential* must have no vaginal intercourse 14 days before 
enrollment or use an effective birth control method ** for 30 days before enrollment 
and agree to continue through visit 2.  
*A woman is considered of childbearing potential unless post- menopausal (>2 years) 
or surgically sterilized (tubal ligation >1 year, bilateral oophorectomy, or hysterectomy).  
**Acceptable birth control methods for the purposes of this study may include abstinence from intercourse with a male partner, monogamous relationship with 
vasectomized partner, male condoms with the use of applied spermicide, intrauterine 
devices, and licensed hormonal methods. A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly . 
6. Able to swallow pills . 
7. W illing to comply with protocol requirements, including availability for follow-up for 
the duration of the study . 
8. Agree to avoid systemic or intravaginal antibiotics* with activity against N. gonorrhoeae from enrollment through Visit 2 (Day 5-10). *Topical and intravaginal 
antifungals are permitted. 
9. Agree to avoid magnesium/aluminum antacids, sucralfate, didanosine, or highly 
buffered drugs, up to 2 hours after receipt of study drug. 
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
19 of 49  
 5.2 Subject Exclusion Criteria  
Subjects meeting any of the following criteria at enrollment will be excluded from the 
study: 
 1. Known renal insufficiency from clinical history . 
2. Use of systemic or intravaginal antibiotics* with potential activity against N. 
gonorrhoeae within 30 days prior to study drug administration. *Topical and 
intravaginal antifungals are permitted. 
3. Use of systemic corticosteroid drugs or other immunosuppressive therapy within 30 days prior to enrollment. 
4. Receipt or planned receipt of an investigational product in a clinical trial within 30 days prior to or 7 days after treatment administration.  
5. Pregnant or breastfeeding. 
6. Clinical diagnosis of pelvic inflammatory disease or genital ulcer . 
7. Confirmed or suspected complicated or systemic gonococcal infection, such as abdominal pain, testicular pain, epididymitis, orchitis, arthritis, or endocarditis . 
8. Receipt of magnesium/aluminum antacids, sucralfate, didanosine, or highly buffered 
drugs, within 6 hours before receipt of study drug. 
9. Mutant N. gonorrhoeae gyrA serine 91 genotype from any anatomic site, as 
determined by the gyr A test assay on a specimen collected within 30 days of 
enrollment. 
10. Known allergy or history of adverse reaction to ciprofloxacin. 
11. Known allergy to quinolones . 
12. Previous enrollment in this study . 
13. Medical condition or other factor that in the judgment of the investigator  might affect 
ability to comply with procedures .  
 
5.3 Subject Withdrawal  
5.3.1 Reasons for Withdrawal 
Subjects may voluntarily withdraw their consent for further study participation at 
any time and for any reason, without penalty. 
 Refer to section 11 for how subjects who withdraw from study participation will be handled in study analyses.   Subjects may withdraw or be withdrawn from the study for any of the reasons 
given below. The reason for withdrawal will be recorded in the data collection 
form.  
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
20 of 49  
 • Subject vomits within 1 hour of study medication administration.  
• Subject receives any systemic antibiotic other than the study  medication prior 
to Visit 2  (Day 5-10).  
• Subject is pregnant or breastfeeding. 
• Discretionary decision by the site investigator . 
• At the discretion of the IRB, NIH, or other government agenc y as part of their 
duties to ensure that research subjects are protected. 
5.3.2 Handling of Withdrawals 
Subjects who withdraw voluntarily prior to receiving ciprofloxacin will be offered 
local standard of care treatment for  N. gonorrhoeae and followed per clinic 
guidelines.   
 
Subjects who withdraw voluntarily or never return after receiving ciprofloxacin and tolerated medication without difficulty will not be contacted for repeat 
gonorrhea testing or treatment.  
Subjects who withdraw voluntarily or never return after being found to be positive 
for N. gonorrhoeae at Visit 2 (Day 5-10) will be contacted by phone and by 
certified mail with instructions that they should follow-up for treatment per local standard of care and should be followed per clinic guidelines.  
5.3.2 .1 Termination of Study  
Although the study sponsor has every intention of completing the study, 
the sponsor reserves the right to terminate the study at any time for 
clinical or administrative reasons. Reasons for termination include, but are not limited to, study closure at the discretion of DMID.  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
21 of 49  
 6 GYRASE A ASSAY /STUDY TREATMENT  
6.1 Gyrase A Assay Description  
Real-time PCR testing protocol: The laboratories participating in this study will  follow the 
testing protocol as described in Siedner et al [15] with modifications. For real -time PCR 
analysis of the gyrA gene, remnant specimens will be subject to nucleic acid (DNA) 
extraction by using automated nucleic acid extraction utilizing either the bioMerieux 
easyMag, or the Qiagen EZ1, or Qiacube platforms, as determined in the optimization 
studies. Extracted samples will be used for real -time PCR. Amplification and melting-
curve analysis of specimens will be performed by using a Roche LightCycler 480 or Light 
Cycler 2.0 platforms (Roche Diagnostics, Pleasanton, CA). Amplified regions of 
the gyrA gene will be assessed for mutations in the Ser 91 codon through use of 
melting-curve analysis with probes specific to that region of the gyrA gene. The probes 
for the serine 91 amplicon ( gyrA-ser-Flu and gyrA-ser-LC) are a paired set of FRET 
probes, including a LightCycler Red640 probe and a fluorescein-labeled probe, 
separated by 1 bp. The Red640 oligonucleotide has a maximal absorption and 
emissions of 622 and 638 nm, respectively. Amplification of PCR product will be followed 
by melt-curve analysis to confirm specificity of amplification and genotype. Melting-curve 
analysis will be performed by using LightCycler software (v.4.0). The s oftware will be 
used to plot the negative value of the first derivative of fluorescence per unit time to 
distinguish peak melting temperatures from melting-curve plots. Designation of predicted 
susceptibility is based upon the observed melting curve parameters as previously 
described [15]. 
6.2 Ciprofloxacin Description 
Ciprofloxacin is a quinolone medication approved by the FDA for the treatment of 
gonorrhea. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the 
monohydrochloride monohydrate salt of 1- cyclopropyl -6-fluoro-1, 4-dihydro-4-oxo -7-
(1piperazinyl) -3-quinolinecarboxylic acid. The molecular weight of the ciprofloxacin 
hydrochloride monohydrate is 385.82. It is a faintly yellowish to light yellow crystalline 
substance.  
6.2.1 Ciprofloxacin Formulation 
Ciprofloxacin 500 m g tablets  
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
22 of 49  
 6.2.2 Ciprofloxacin Acquisition 
Ciprofloxacin will be purchased centrally, and upon request by DMID, will be 
transferred to the following address:  
DMID Clinical Agents Repository (CAR)  
XXXXXXXXXX 
 
Ciprofloxacin will be shipped from the DMID CAR to the study site upon request 
and approval by DMID.  
6.2.3 Storage and Stability  
Ciprofloxacin is stable at room temperature. Stability of this medication will be 
maintained by storing the drug below 30°C (86°F). The storage room temperature will be monitored on business days . 
6.2.4 Dosage Preparation and Administration 
Ciprofloxacin tablets will be administered orally and can be taken with or without 
food. Subjects will receive 500mg and will be directly observed.  
6.2.5  Accountability Procedures 
Fisher repository will ship packaged ciprofloxacin  to the investigational sites. At 
each site, medication packages will be kept in a locked storage cabinet at the 
clinic and administered by the study personnel. Accountability records will be 
maintained by designated site staff (i.e., study personnel or pharmacy staff). 
Unused study treatment will be destroyed or returned to Fisher BioServices at 
the end of the study. Unused study treatment will not be destroyed without DMID 
approval. 
6.2.6 Assessment of Subject Compliance 
Medication will be given and directly observed by the study staff and recorded in 
the subject’s case report form ( CRF). Since medication will be directly observed, 
there will be no need for return of study medication packaging or a medication 
diary at the follow -up vi sit. 
6.2.7 Concomitant Medications 
Administration of any contraindicated medications or new antibiotics after 
enrollment will be recorded on the appropriate data collection form. Contraindicated medications will include all medications contraindicated with 
ciprofloxacin (described in section 5.2) taken 30 days prior to signing the informed consent form through Visit 2 or early termination, whichever occurs 
first.    
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
23 of 49  
 Subjects who have received study medication and are subsequently diagnosed 
with a concomitant infection, which requires systemic antibiotics will receive 
treatment according to the local clinic’s standard of care.  
Use of new medication should prompt evaluation for the presence of a new 
diagnosis of chronic medical disease or condition. 
Oral contraceptives are allowed, as they do not alter the metabolism of 
ciprofloxacin .   
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
24 of 49  
 7 STUDY SCHEDULE 
Complete study schedule details listed by study visit day are described below. Refer also to 
Appendix A.  
7.1 Visit 1, Day 1 ( Screening/Enrollment)  
Screening and enrollment will o ccur at the same clinic visit. Potential subjects will be 
informed about the study and invited to participate. Subjects who are interested in the 
study will be asked to sign a consent form that will describe the purpose of the study, the 
procedures to be followed, the risks and benefits of participating, and will include a separate section for consent to store samples for future use. A copy of the consent form 
will be given to the subject and this fact will be documented in the CRF . 
 The following will be performed for s ubjects who give informed consent: 
 1. Demographic information including age, sex, and gender will be collected from the subject  
2. Eligibility criteria will be reviewed with the subject  
3. Discuss pertinent medical history for  assessment of specif ic symptoms that are 
potentially related to fluoroquinolone use as described in section 9, Assessment of 
Safety, and sexual history will be obtained by interview of subjects to assure eligibility. Concomitant infections will be reviewed. 
4. Review of signs and symptoms  within the past 7 days  
5. All new antibiotics  or concomitant medications contraindicated with ciprofloxacin 
taken in the 30 days prior to signing the informed consent will be recorded on the appropriate data collection form  
6. Targeted physical exam  
7. Speculum exam for females  
Note: Women diagnosed with BV by local standard test at Visit 1 will receive 
treatment for BV at Visit 2 according to local standard of care. 
8. Urine pregnancy test for females of childbearing potential 
9. One swab for N. gonorrhoeae culture and one swab for NAAT  and gyrA serine 91 
genotype from the throat* 
10. One swab for N. gonorrhoeae culture and one swab for NAAT  and gyrA serine 91 
genotype from the rectum * 
11. One swab for N. gonorrhoeae culture from the urethra (males)* 
12. U rine specimen for NAAT and gyrA serine 91 genotype (males)* 
13. Cervical swab for N. gonorrhoeae culture ( females)*  
14. Cervical or vaginal swab for NAAT and gyrA serine 91 genotype (females)*  
*Note  1: O nly at the suspected infected anatomical site based on prior test results  or 
other sites as clinically indicated  
*Note 2: G yrA assay is required only if NAAT is positive 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
25 of 49  
 15. Once swabs have been collected, and all eligibility criteria have been assessed, 
subjects will receive one dose of ciprofloxacin 500 mg by mouth under direct 
observation with the date and time of administration documented.  
• Subjects will be observed for at least 5 minutes after administration of 
ciprofloxacin . 
• Subjects will be instructed to return to the clinic or to contact the study site 
coordinator immediately if they vomit within 1 hour of receiving study medication.  
• Subjects who vomit within 1 hour of study drug administration will be retreated for 
N. gonorrhoeae infection with an alternative recommended regimen per the local 
standard of care.  
16. Reminder to abstain from sexual intercourse or use condoms during any sexual contact until the Test of Cure Visit (Visit 2, Day 5-10) is complete   
17. Reminder to bring sex partners in for testing and treatment, if needed 
18. Reminder to return for Visit 2  (Day 5-10)  
7.2 Visit 2, Day 5- 10 (Test of Cure Visit)  
Subjects will have the following: 
 1. Interim medical history for  assessment of  specific symptoms that are potentially  
related to fluoroquinolone use as described in section 9, Assessment of Safety, and 
interim sexual history  
2. Review of signs and symptoms  at site of infection since the previous visit 
3. Review of new antibiotics or concomitant medications  contraindicated with 
ciprofloxacin  
4. Targeted physical exam  
5. One swab for N. gonorrhoeae culture and one swab for NAAT and gyrA serine 91 
genotype from the throat* 
6. One swab for N. gonorrhoeae culture and one swab for NAAT and gyrA serine 91 
genotype from the rectum*  
7. One swab for N. gonorrhoeae culture from the urethra (males)* 
8. Urine specimen for NAAT and gyrA serine 91 genotype (m ales)* 
9. Cervical swab for N. gonorrhoeae culture (females)*  
10. Cervical or vaginal swab for NAAT and gyrA serine 91 genotype (females)*  
*Note 1: Repeat samples to be collected only from those anatomical sites swabbed 
for N. gonorrhoeae culture or NAAT at Visit 1   
*Note 2: G yrA assay is required only if NAAT is positive 
11. Reminder to b ring sex partners in for testing and treatment, if needed  
12. Reminder that test results will be provided to subjects by phone call (Visit 3, Day 11-
14) 
 Women diagnosed with bacterial vaginosis  (BV) will receive treatment according to local 
standard of care. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
26 of 49  
 7.3 Visit 3, Day 11 to 14 ( Test of Cure Results)  
1. Test results will be provided to subjects by phone c all.  
2. Subjects whose Visit 2 (Day 5-10) N. gonorrhoeae culture and NAAT results are 
negative will have completed participation in the study; no further follow -up is 
required. 
3. Subjects who are N. gonorrhoeae culture positive or NAAT positive will be referred 
for standard of care treatment for N. gonorrhoeae. 
4. Reminder to bring sex partners in for testing and treatment, if needed 
7.4 Unscheduled/Early Termination  Visit  
For an unscheduled visit at the subject’s request or the site investigator’s 
recommendation, subjects will have the following:   1. Interim medical history  for assessment of specific symptoms that are potentially 
related to fluoroquinolone use as described in section 9, Assessment of Safety, and 
interim sexual history  
2. Review of signs and symptoms  at site of infection since the  previous visit  
3. Review of new antibiotics or concomitant medications  contraindicated with 
ciprofloxacin  
4. Targeted physical exam   
5. Reminder to abstain from sexual intercourse or use condoms  during any sexual 
contact until the Test of Cure Visit (Visit 2, Day 5-10) is complete 
6. Reminder to bring sex partners in for testing and treatment, if needed 
7. Reminder to return for follow -up visit  
 
For an early termination visit, subjects will have the following:  
 1. Interim medical history  for assessment of specific symptoms that are potentially 
related to fluoroquinolone use as described in section 9, Assessment of Safety, and 
interim sexual history  
2. Review of signs and symptoms  at site of infection since the previous visit  
3. Review of new antibiotics or concomitant medications contraindicated with ciprofloxacin  
4. Targeted physical exam  
5. Reminder to bring sex partners in for testing and treatment, if needed  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
27 of 49  
 8 STUDY PROCEDURES/EVA LUATIONS  
8.1 Clinical Evaluations 
Discuss pertinent medical history  for assessment of specific symptoms that are 
potentially related to fluoroquinolone use as described in section 9, Assessment of 
Safety , and sexual history (including assessment of signs and symptoms) will be 
obtained by interview of the subjects at Visit 1 prior to study treatment. Subjects will be 
asked if they can swallow pills.  
 
• For female cervicovaginal infections, subjects will be classified as symptomatic if 
they report any of the following symptoms: abnormal vaginal discharge, abnormal 
vaginal bleeding, or pain during intercourse.  
• For male urethral infections, subjects will be classified as symptomatic if they report 
any of the following symptoms: urethral discharge or pain with urination.  
• For testing of rectal swab specimens, subjects will be classified as symptomatic if 
they report any of the following symptoms: anorectal pain, ano rectal discharge, or 
anorectal bleeding.  
• For testing of pharyngeal swab specimens, subjects will be classified as symptomatic if they report having a sore throat.  
• For all specimen types, subjects will be considered asymptomatic if they do not endorse these s ymptoms. 
 At Visit 2 (Day  5-10) and unscheduled visits, an interim medical history will be obtained 
by interview if the subject notes any changes since the previous visit in specific 
symptoms that are potentially related to fluoroquinolone use as described in section 9, 
Assessment of Safety. The interim medical history should include an assessment for new medical conditions.  
 Sexual history including sexual orientation will be obtained by interview of the subjects at Visit 1. At Visit 2 (Day 5-10) and unscheduled visits, subjects will be queried regarding 
sexual activity and condom use since the previous clinic visit. 
 
Medications history (concomitant medications contraindicated with ciprofloxacin) will 
include a review of all current medications and medications taken 30 days prior to study enrollment. Assessm ent of eligibility will also include a review of all permitted and 
prohibited medications per the Subject Inclusion and Exclusion Criteria (see s ection 5). 
 
A targeted physical exam will be performed based on subject’s clinical history. The exam will be performed by appropriate study personnel to assess general physical condition and will at a minimum include the following areas/systems: throat, genitals, and rectum. A speculum exam will be performed on females. All physical examinations will be 
performed by a study clinician licensed to make medical diagnoses. At visits following 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
28 of 49  
 Visit 1, a targeted physical examination may be conducted based on interim medical 
history . 
 
8.2 Laboratory Evaluations  
8.2.1 Clinical Laboratory Evaluations 
Prior to the study implementation period, each laboratory will verify the 
performance of the gyr A serine 91 genotype real -time polymerase chain reaction 
with fluorescent hybridization probe detection assay, to meet the CLIA 
requirements, including accuracy, precision, limit of detection, interfering 
substances , and normal values. Full details of the verification protocol and gyrA 
serine 91 genotype assay standard operating procedure ( SOP ) are in the study’s 
Manual of Procedures.  
 
Specimens positive for gonococcal DNA or RNA from the participating clinical 
sites will be tested by PCR for detection of wild- type gyrA serine 91 genotype. 
Subjects who have been treated empirically (i.e., symptomatic subjects ) may opt 
out of this testing, if indicated by the clinical site on the laboratory  requisition. 
 
The presence or absence of mutations in the gyrA  gene will be determined by 
real-time PCR. For real -time PCR analysis of the gyrA gene, remnant NAAT 
specimens will be extracted, using either a Roche MagNAPure instrument or Qiacube, which will then be used for the gyrA real-time PCR, using a Roche 
LightCycler platform. The gyrA assay combines amplification of the gyrA gene in 
the serine 91 coding region and melting-curve analysis of to determine wild-type 
vs. mutation in this region. This is done through use of Fluorescence Resonance Energy Transfer (FRET) probes for the s erine 91 amplicon.   
8.2.2 Special Assays or Procedures for Enrolled Subjects 
Urine collected at Visit 1 will be analyzed for detecting pregnancies by use of a 
standard rapid urine βhCG assay.  
 Swabs (non-cotton) will be used to collect specimens at each site (throat, rectal, 
urethral or cervical) for N. gonorrhoeae culture. The swab will be immediately 
smeared onto a modified Thayer Martin plate, which is placed into a candle jar or 
other CO
2-rich transport media, at the clinic. These plates will be transported in 
the CO 2-rich transport media to the local laboratory for culture for N. 
gonorrhoeae. The local laboratory  will culture and isolate the gonococcal strain, 
according to their SOP for N. gonorrhoeae culture. N. gonorrhoeae culture 
specimens will be obtained first; this sequence maximizes the load collected, which increases the likelihood of a successful culture. A second swab or urine 
will be collected for NAAT for N. gonorrhoeae detection, according to the 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
29 of 49  
 laboratory SOP, using a collection kit with liquid transport specific to the local 
protocols (e.g. unisex swab specimen collection kit).  
 
For each positive culture (regardless of anatomical site or visit number), a subculture of each gonococcal isolate will be subject to antimicrobial susceptibility testing using the agar dilution method for azithromycin, cefixime, ceftriaxone, ciprofloxacin, gentamicin, penici llin, spectinomycin, and tetracycline. 
M100 Clinical and Laboratory Standards Institute (CLSI) interpretive criteria will be used to evaluate susceptibility to each agent, with the exception of azithromycin, where CDC criteria will be used [1 6].  
 For each positive NAAT, or negative NAAT with a positive culture for the same 
visit, up to two 500 
uL aliquots of the specimen will be frozen in screw-top 2.0 mL 
tubes, at -7 0̊C for discordant resolution, if needed. These frozen remnants  will be 
stocked  at the local laboratory until they are sent to the central laboratories 
approximately halfway through the study and at study completion. 
 
For subjects who demonstrate culture-bas ed antibiotic resistance to ciprofloxacin 
but are deemed ciprofloxacin-susceptible by the gyrA gene-dependent 
mechanism, or have culture positivity at Visit 2 , whole genome sequencing will 
be performed on their  N. gonorrhoeae isolates  from all visits . DNA samples will 
be extracted from the cultures and multiplexed libraries will be created. Sequencing will be performed according to the laboratory SOP using a platform 
such as the MiSeq (Illumina, San Diego, CA). Genomic assembly and annotation 
will be performed using sequenced N. gonorrhoeae strains as reference 
scaffolding and phylogenetic analyses will be conducted based on nucleotide polymorphisms [17]. 
 Specific instructions and numbering schemes for study isolates and specimens are 
described in the study’s Manual of Procedures.  
8.2.3 Specimen Preparation, Handling, and Shipping 
8.2.3.1 Instructions for Specimen Preparation, Handling, and Storage  
 
Stocked clinical isolates of N. gonorrhoeae and remnant specimens will 
be stored at the performing laboratory site until they are sent to the 
central laboratories approximately halfway through the study and at the 
end of the study.  
 
Specific instructions for specimen preparation, handling, and storage 
are described in the study’s Manual of Procedures. 
 
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
30 of 49  
 8.2.3.2 Specimen Shipment 
 
Bacterial isolates will be shipped frozen on dry ice in accordance with 
IATA shipping regulations. N. gonorrhoeae DNA remnant specimens will 
be shipped to the reference laboratory frozen on dry ice at specified 
intervals in accordance with IATA shipping regulations. Specimens will 
be shipped as category B (infectious) substances to meet the 
requirements outlined in 49 CFR 178.609.  
  Specimens and isolates for use/long -term storage will be shipped to: 
 
ATTN: DeeDee Pacheco, Laboratory Manager  
University of C alifornia San Diego AVRC  
 XXXXXXXXXX 
 
Specific instructions for specimen shipment will be described in the study’s Manual of Procedures. 
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
31 of 49  
 9 ASSESSMENT OF SAFETY 
Ciprofloxacin has a well -established safety profile and has been prescribed to several 
millions of people in the US and worldwide as it was the CDC’s recommended treatment 
regimen for uncomplicated gonorrhea from 1993 to 2007. Therefore, adverse event assessment is not required for this study.  
 In order to address the FDA Drug Safety Communication dated May 12, 2016, regarding 
fluoroquinolone use for certain uncomplicated infections, subjects will be asked at Visit 
1, Visit 2, and any Unscheduled or Early Termination Visit if they have experienced any 
serious side effects related to fluoroquinolone use. These include tendon pain, joint pain, 
muscle pain, tingling or pricking sensation, confusion, and hallucinations. This 
information will be recorded in the study source documents as a change in health status. Any subject who experiences such an event will be given instructions on how to submit a 
MedWatch Consumer Voluntary Reporting Form to the FDA if they desire. 
 
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
32 of 49  
 10 CLINICAL MONITORING  
10.1 Site Monitoring Plan 
Site monitoring is conducted to ensure that the human subject protections, study and 
laboratory procedures, study intervention administration, and data collection processes 
are of high quality and meet sponsor  requirements , ICH/GCP guidelines and applicable 
regulations, and that the study is conducted in accordance with the protocol, protocol -
specific Manual of Procedures and applicable sponsor standard operating procedures. 
DMID, the sponsoring agency, or its designee, will conduct site-monitoring visits as 
detailed in the clinical monitoring plan.  
 
Site visits will be made at standard intervals as defined by DMID and may be made more 
frequently as directed by DMID. Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, electronic case report forms (eCRFs ), 
informed consent forms, source documents necessary to support the documentation 
entered into the eCRFs, and protocol and GCP compliance. Site monitors will have 
access to the study site, study personnel, and all study documentation according to the DMID -approved site monitoring plan. Study monitors will meet with site principal 
investigators to discuss any problems and actions to be taken and will document visit 
findings and discussions. 
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
33 of 49  
 11 STATISTICAL CONSIDER ATIONS  
11.1 Study Hypotheses  
The primary objective of  the study is to clinically validate a gyrA assay used to determine 
ciprofloxacin  susceptibility in the treatment of uncomplicated gonococcal infection by 
assessing the efficacy of ciprofloxacin for treatment of uncomplicated N. gonorrhoeae 
infections with serine 91 gyrA genotype as identified by the gyrA assay.  
 
The study is designed to test the following hypothesis in the primary efficacy analysis conducted in the p er-protocol (PP) analysis population:  
 Null hypothesis: The proportion of ciprofloxacin-su sceptible (as identified by the gyrA 
assay) N. gonorrhoeae-infected subjects with microbiological cure 5-10 days after 
receiving ciprofloxacin is less than 0.95.  
Alternative hypothesis: The proportion of ciprofloxacin-susceptible (as identified by the 
gyrA assay) N. gonorrhoeae-infected subjects with microbiological cure 5-10 days after 
receiving ciprofloxacin is at least 0.95. 
 The cut-off of 0.95 was chosen based on the CDC criteria for treatments of 
uncomplicated N. gonorrhoeae infections. The criterion for recommended treatments is a 
cure rate of greater than 95% with a lower bound of the 95% confidence interval  of least 
95%.  The criterion for alternative treatments is a cure rate of greater than 95% with a 
lower bound of the 95% confidence interval  of at least 90%.  
11.2 Sample Size Considerations 
The primary analysis will compute the proportion of ciprofloxacin-susceptible N. 
gonorrhoeae-infected subjects with microbiological cure 5-10  days after receiving 
ciprofloxacin  in the PP analysis population. The confidence interval for the 
microbiological cure proportion will be computed using a one- sided modified Jeffreys 
interval using a significance level of 0.05. Power calculations were performed via a simulation study based on 10,000 replications assuming a 98% microbiological cure 
rate.   
 
Figure 11.2 below presents the power available to test that the microbiological cure rate 
is at least 95% (i.e., lower bound of the one-sided confidence interval is at least 95%) 
across a  range of evaluable sample sizes. Here, evaluable denotes eligible for the PP 
analysis population. The power reaches 80% at a sample size of 195 evaluable subjects; however, since the power curve is not monotonic, sample sizes directly on either side of 
195 are below 80%. Since the exact number of evaluable subjects at the end of the study is difficult to predict, an evaluable target of 257 subjects is chosen to ensure at 
least 80% even if the exact number of evaluable subjects at the end of the study differs 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
34 of 49  
 slightly from 257. With a target of 257, the power available is approximately 85% and we 
can fall at most 10 subjects short (sample size of 247 evaluable subjects) and still 
ensure 80% power. Any sample size greater than 257 will ensure at least 80% power.    
 Figure 11.2: Power Available to Test That the Microbiological Cure Rate I s at Least 95%  
 
To calculate the number of subjects required to enroll to reach 257 subjects in the PP 
analysis population, the following assumptions are made:  
• 25% of enrolled subjects will be culture negative at baseline.  
• 10% of subjects will be excluded from the PP analysis population (reasons for exclusion are stated in s ection 11.4.1)  
 
Under these assumptions, enrolling 381 subjects will provide 257 subjects in the PP analysis population. Since the proportion of subjects who will be culture negative at 
baseline can vary depending on a number of factors, 25% is a rough estimate. The exact 
number of subjects needed to provide 257 subjects in the PP analysis population may vary from 381, so 381 is an approximate enrollment target. 

 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
35 of 49  
 11.3 Planned Analyses  
11.3.1 Planned Futility  Review  
The study will be monitored for futility. The number of treatment failures among 
subjects eligible for the PP analysis population will be monitored by a statistician independent from the study team.  If, at any point in the trial, 30 subjects eligible 
for the PP analysis population are classified as treatment failures, then the statistician will notify DMID to consider termination of the tri al. 
 
The cut-off was chosen because 29 or fewer treatment failures among 257 
subjects eligible for the PP analysis population would result in a lower bound of the one-sided 95% Jeffreys confidence interval greater than or equal to 85%. Under the protocol’s  assumptions of the cure rate, a simulation study based on 
50,000 replications found that the operating characteristics (power and type-I 
error) of this futility review do not vary from those described in section 11.2. 
11.4 Final Analysis Plan  
A separate statistical analysis plan document will be generated that will contain the 
details of the analyses. This section outlines the major components of the analyses.  
11.4.1 Analysis Populations 
Per-Protocol (PP) Population: This analysis population includes enrolled subjects  
who met all inclusion/exclusion criteria, have N. gonorrhoeae isolated on Day 1 
culture from the rectum or urogenital site, have an evaluable microbiological 
outcome status (see section 11.4.3 .1), complied with study treatment, did not 
receive any contrai ndicated medication or systemic antibiotic other than the study 
medication for any concomitant infection prior to Visit 2 (Day 5-10), and returned 
for their Visit 2 (Test of Cure) visit within window. 
 
To be compliant with study treatment, a subject must be able to swallow the pill and not vomit within 1 hour of administration.  
 For the primary analysis, subjects need only have N. gonorrhoeae isolated on 
Day 1 culture from the rectum or urethra (male) or cervix/vagina (female). For the analysis of secondary objective 1, subjects need to have N. gonorrhoeae isolated 
on Day 1 culture at the particular site being assessed.   In addition, alternate per -protocol analyses  which exclude subjects with reported 
concomitant infection/disease/procedure that may interfere with study product, 
use of concomitant medications or products that may interfere with study product, 
significant protocol deviations, and other events that may impact study product 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
36 of 49  
 effectiveness or study analyses will be explored.  Details will be described in the 
separate statistical analysis plan.   
 
Microbiological Intent-to-T reat (micro-ITT) Population:  This analysis population 
includes all enrolled subjects who have N. gonorrhoeae isolated from the rectum 
or urogenital site on Day 1 culture.   
 For the primary analysis, subjects need only have N. gonorrhoeae isolated on 
Day 1 culture from the rectum or urethra (male) or cervix/vagina (female). For the 
analysis  of secondary objective 1, subjects need to have N. gonorrhoeae isolated 
on Day 1 culture at the particular site being assessed.  
 
Intent-to-Treat (ITT) Population:  This analysis population includes all enrolled 
subjects.   
 Subjects who receive any treatment other than the study medication for their N. gonorrhoeae infection will be included in all efficacy analyses as treatment 
failures.  
11.4.2 Baseline Characteristics 
Baseline and demographic characteristics will be summarized. For  both 
continuous and categorical variables, appropriate summary statistics will be 
applied. For continuous variables, descriptive statistics will include the number of non-missing values, mean, standard deviation, median, minimum, and maximum.  
For categorical variables, descriptive statistics will include counts and 
percentages per category.  
11.4.3 Efficacy and Other Analysis Plan  
In this section, the primary and secondary analyses are described. The exploratory analysis will be addressed in the statistical analysis plan and is not described here. 
11.4.3.1 Primary Analysis  
The primary analysis will test whether the microbiological cure rate of 
ciprofloxacin in subjects infected with gyrA serine 91 genotype N. 
gonorrhoeae is greater than or equal to 95%. The cure rate will be 
estimated by the proportion of subjects infected with gyrA serine 91 
genotype N. gonorrhoeae with microbiological cure at Visit 2 (D ay 5-10).   
 
Microbiological outcome status for the primary analysis is evaluated at Visit 2 (Day 5-10) and is defined as follows:  
• Microbiological Cure: N. gonorrhoeae not detectable by culture from 
all anatomical sites that had detectable N. gonorrhoeae at Visit 1.  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
37 of 49  
 • Microbiological Failure: N. gonorrhoeae detectable by culture from at 
least one anatomical site that had detectable N. gonorrhoeae at Visit 
1. 
• Non-evaluable: At least one of the following: Subject did not return 
for Visit 2 ( Day 5-10), or culture results at Visit 2 ( Day 5-10) were not 
available for any reason, or subject could not be evaluated for 
microbiological outcome status for any other reason.  
 
For the PP analysis population, subjects with non-evaluable outcome status will be excluded from the analysis. For the micro-ITT and ITT analysis populations , subjects with non-evaluable outcome status will be 
included in analyses and classified as treatment failures. Subjects who discontinued early from the study due to a lack of treatment effect are included in all analysis populations as treatment failures. 
 
The test will be performed by calculating the one- sided 95% modified 
Jeffreys confidence interval and comparing it to the value 0.95. T he 
modification to the Jeffreys confidence interval was introduced in Brown, Cai, and DasGupta [18 ]. The lower bound of the confidence interval will 
be calculated as follows:  
 
If the number of cures, denoted X, is less than the number of subjects included in the analysis, denoted N, then the lower bound of the one-sided 95% confidence interval is: 
 
𝐵𝐵(0.95;𝑋𝑋+ 0.5;𝑁𝑁 −𝑋𝑋 + 0.5)   
 
where 𝐵𝐵(𝛼𝛼;𝑚𝑚
1;𝑚𝑚2) denotes the α  quantile of a Beta(m 1, m 2) distribution.  
 If the number of cures is equal to the number of subjects included in the analysis, denoted N, then the lower bound of the one-sided 95% confidence interval is: 
(0.05)
1/𝑁𝑁 
 
The primary analysis will be performed in the PP analysis population.  Secondary analyses of the primary outcome measure will be performed in the micro-ITT and ITT analysis populations. Sensitivity analyses  may 
be performed to assess the impact of the choice of confidence interval .  
These analyses will be specified in the statistical analysis plan.  
11.4.3.2 Secondary Analyses  
The analysis of the efficacy of by anatomic site (secondary objective 1) will proceed as described in s ection 11.4.3 .1 where the modification to 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
38 of 49  
 the definition of microbiological outcome status is provided below.  
Summaries of the cure rate estimate and associated confidence interval 
and hypothesis test will be generated for each individual anatomic site.   
 For the analysis of s econdary objective 1, microbiological outcome 
status at each anatomical site is evaluated at Visit 2 (Day 5-10) and is defined for a particular anatomical site as follows:  
 
• Microbiological Cure: N. gonorrhoeae not detectable by culture at 
the particular anatomical  site that had detectable N. gonorrhoeae at 
Visit 1 . 
• Microbiological Failure: N. gonorrhoeae detectable by culture at the 
particular  anatomical site that had detectable N. gonorrhoeae at Visit 
1. 
• Non-evaluable: At least one of the following: Subject did not return 
for Visit 2 ( Day 5-10), or culture results at Visit 2 ( Day 5-10) were not 
available for any reason, or subject could not be evaluated for 
microbiological outcome status for any other reason.  
 
For the analysis of the sensitivity of the gyrA assa y for the detection of 
ciprofloxacin -susceptible N. gonorrhoeae infections (secondary 
objective 2), the sensitivity will be estimated by calculating the proportion of enrolled subjects who have ciprofloxacin-susceptible N. 
gonorrhoeae as identified by culture-based antimicrobial susceptibility 
testing at Visit 1.  The proportion of enrolled subjects who do not have ciprofloxacin -susceptible N. gonorrhoeae will also  be estimated. This 
analysis will be performed in the micro-ITT analysis population. Secondary and sensitivity analyses, which will assess the impact of analysis population and missing antimicrobial susceptibility testing, may 
be performed. These analyses will be specified in the separate statistical 
analysis plan document. 
11.4.3.3 Exploratory Analysis   
The exploratory  analysis will be described in the separate statistical 
analysis plan. 
   
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
39 of 49  
 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate research records for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects. As part of participating in a DMID -sponsored 
study, each site will permit authorized representatives of the DMID, its designees, and appropriate regulatory agencies to examine (and when required by applicable law, to 
copy) study  records for the purposes of quality assurance reviews, audits, and 
evaluation of the study safety and progress. These representatives will be permitted 
access to all study source data. Study source data are all information, original records of 
clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
40 of 49  
 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, the participating site is 
responsible for conducting routine quality assurance (QA) and quality control (QC) 
activities to internally monitor study progress and protocol compliance. The site principal investigator will provide direct access to all trial -related sites, source data/data collection 
forms, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities. The site principal investigator will ensure all study personnel are appropriately trained and applicable documentations are 
maintained on site.  
 
The Statistical Data and Coordinating Center ( SDCC) will implement quality control 
procedures beginni ng with the data entry system and generate data quality control 
checks on the database. Any missing data or data anomalies will be communicated to 
the site for clarification and resolution.  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
41 of 49  
 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1 Ethical Standard  
This study will be conducted in full conformity with the Declaration of Helsinki, or with the 
ICH-GCP regulations and guidelines, whichever affords the greater protection to the 
subject.  
 The investigator will also ensure that this study is conducted in full conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the US National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research (April 18, 1979) 
and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations 25691 (1997). 
14.2 Institutional Review Board  
Each participating institution will provide review and approval of this protocol and the  
associated informed consent documents and recruitment material by an appropriate 
independent ethics committee (IEC) or IRB registered with the Office for Human 
Research Protections (O HRP ). Any amendments to the protocol or consent materials 
will also be approved before they are placed into use. In the United States and in other 
countries, only institutions holding a current US Federalwide Assurance issued by OHRP may participate. 
14.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the subject agreeing to participate 
in the s tudy and continuing throughout the subject’s  study participation.  Extensive 
discussion of risks and possible benefits of this therapy will be provided to the subjects and their families. Consent forms describing in detail the study  treatment , procedur es, 
and risks are given to the subject and written documentation of informed consent is required prior to administering study treatment. Consent forms will be IRB -approved and 
the subject will be asked to read and review the document. Upon reviewing the document, the investigator will explain the research study to the subject and answer any questions that may arise. The subject will sign the informed consent document prior to any procedures being done specifically for the study. The subject should have the opportunity to discuss the study with his/her  surrogates or think about it prior to agreeing 
to participate. The subject may withdraw consent at any time throughout the course of the trial.  A copy of the informed consent document will be given to the subject.   The 
rights and welfare of subjects will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  
 
 
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
42 of 49  
  
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
 
This trial will be inclusive of all adults who meet the s ubject inclusion/e xclusion criteria, 
regardless of religion, sex, or ethnic background. Should the outcome of this trial be deemed acceptable, additional trials may be initiated in other populations. The demographic and ethnic distribution of the study population will be generally reflective of the distribution of subjects with N. gonorrhoeae within each STD clinic. The following 
populations will be excluded from study participation:  
 
• Pregnant women  
Pregnant women are excluded from this study, as it is not known if ciprofloxacin will 
harm  a fetus .  
 
• Children 
The NIH has mandated that children (defined as anyone under the age of 21) be included in research trials when appropriate. This study will enroll children aged 18 to 
20 who are able to give informed consent. This study meets "Justifications for 
Exclusion" criteria for younger children as set forth by the NIH. Specifically, 
"insufficient data are available in adults to judge potential risk in children" and "children should not be the initial group to be involved in research studies."  
14.5 Subject Confidentialit y 
Subject confidentiality is strictly held in trust by the participating investigators, their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to participating  subjects.  
 The study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to 
any unauthorized third party without prior written approval of the sponsor. 
 To further protect the privacy of study subjects, we have a Certificate of Confidentiality from the National Institutes of Health (NIH). This certificate protects identifiable research information from forced disclosure. It allows the investigator and others who have access 
to research records to refuse to disclose identifying information on research participation 
in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By protecting researchers and institutions from being compelled to disclose information that would identify research subjects, Certificates of Confidentiality help achieve the research objectives and promote participation in studi es 
by helping assure confidentiality and privacy to subjects.  
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
43 of 49  
 Applicable regulatory authorities, such as the FDA, or other authorized representatives 
of the sponsor may inspect all study documents and records required to be maintained 
by the investigator.  The clinical study site will permit access to such records. 
14.6 Study Discontinuation 
If the study is discontinued, subjects will be given appropriate care and treatment for 
gonorrhea under medical supervision until the infection has resolved.  
14.7 Future Use of  Stored Specimens 
All gonococcal strains will be stored in a secured location and may be subject to 
additional future testing by authorized staff to better understand resistant gonorrhea. The 
strains  will not be stored with any personal identifying information but will include a new 
unique subject ID number so that specimens from the same individual are linked but the 
subject’s identify will remain unknown. The samples will not contain human genetic material. Future tests will be limited to those related to the study of N. g onorrhoeae and 
not of any human material. The informed consent process will include appropriate 
consent to obtain and store these samples. At the time of informed consent, subjects 
may choose to withhold permission for storage of their specimens and may continue in the study if they decline permission. Specimens from subjects not consenting to storage and future research will be destroyed at the end of the study. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
44 of 49  
 15 DATA HANDLING AND RE CORD KEEPING  
The site principal investigator is responsible to ensure the accuracy, completeness, 
legibility, and timeliness of the data reported.   
 Data collection forms will be derived from the eCRF and provided by the SDCC to record and maintain data for each subject enrolled in the study. All data collection forms should be completed in a neat, legible manner to ensure accurate interpretation of data.  Black 
or blue ink is required to ensure clarity of reproduced copies. When making a change or 
correction, cross out the original entry with a single line and initial and date the change.  
DO NOT ERASE, OVERWRITE, OR USE CORRECTI ON FLUID OR TAPE ON THE 
ORIGINAL.  
 
Data reported in the eCRF derived from the data collection forms should be consistent 
with the data collection forms or the discrepancies should be explained. 
The sponsor and/or its designee will provide guidance to site principal investigators and other study personnel on making corrections to the data collection forms and eCRF. 
15.1 Data Management Responsibilities 
All data collection forms and laboratory reports must be reviewed by the clinical team and data entry personnel, who will ensure that they are accurate and complete.  
 Data collection is the responsibility of the study personnel at the participating sites under the supervision of the respective site principal investigator. During the study, the site principal investigator must maintain complete and accurate documentation for the study.  
 The Emmes Corporation will serve as the SDCC for this study and will be responsible for 
data management, quality review, analysis, and reporting of the study data.  
15.2 Data Capture Methods 
Clinical ( including, but not limited to, concomitant medications, medical history, physical 
assessments , clinical laboratory values ) and endpoint data will be entered into a 21 CFR 
11-compliant Internet d ata entry s ystem provided by the SDCC. The data system 
includes password protection and internal quality checks, such as automatic range 
checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data 
will be entered directly from the data collection forms completed by the study personnel . 
15.3 Types of Data 
Data for this  study will include clinical, laboratory, demographic, behavioral variables , 
and outcome measures. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
45 of 49  
 15.4 Timing/Reports 
A final report will be prepared following the availability of all the safety and laboratory 
data. Interim statistical reports may be generated as deemed necessary and appropriate 
by DMID.   
15.5 Study Records Retention 
Study records and reports, including, but not limited to, CRFs, source documents, informed consent forms (except for future use informed consent forms), laboratory test results, and medication inventory records, shall be retained for 2 years after the last marketing application is approved for the device and until there are no pending or 
contemplated marketing applications.  If an application is not approved for the device, 
study documents should be retained at least 2 years after clinical development of the 
device for investigational use is discontinued and the FDA has been so notified. The site must contact DMID for authorization prior to the destruction of any study records. No records will be destroyed without the written consent of the sponsor. I t is the 
responsibility of the sponsor to inform the investigator when these documents no longer need to be retained. Informed consent forms for future use will be maintained as long as 
the sample exists. 
15.6 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures requirements. The noncompliance may be either on the part of the 
subject, the investigator, or the study personnel. As a result of deviations, correcti ve 
actions are to be developed by the site and implemented promptly.  
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, section 5.1.1 
5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
 
It is the responsibility of the site principal investigator and other study personnel to use continuous vigilance to identify and report deviations within 5 working days of identification of the protocol deviation, or within 5 working days of the scheduled protocol -required activity. All deviations must be promptly reported to DMID, via T he 
Emmes Corporation’s AdvantageEDC
SM. 
 All deviations from the protocol must be addressed in study subject source documents.  A completed copy of the DMID Protocol Deviation Form must be maintained in the regulatory file, as well as in the subject’s source document. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site principal investigator and other  
study personnel are responsible for knowing and adhering to their IRB/IEC requirements. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
46 of 49  
 16 PUBLICATION POLICY  
The NIH Public Access Policy ensures the public has access to the published results of 
NIH funded research. It requires investigators to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon 
acceptance for publication. Further, the policy stipulates that these papers must be accessible to the public on PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) no later 
than 12 months after publication.  
 
Refer to: 
• NIH Public Access Policy, http://publicaccess.nih.gov/ • NIH OER Grants and Funding, http://grants.nih.gov/grants/oer.htm  Following completion of the study, the lead principal investigator is expected to publish 
the results of this research in a scientific journal. The International Committee of Medical 
Journal Editors (ICMJE) member journals have adopted a trials -registration policy as a 
condition for publication. This policy requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine [19]. Other biomedical journals are considering adopting similar 
policies.  
 The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., Phase I trials), 
would be exempt from this policy. Results of any exploratory analysis will not be 
published prior to publication of the primary results for this study.  
All clinical trials supported by the NIH must be registered on ClinicalTrials.gov.  As part 
of the result posting, a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be included in the post on ClincialTrials.gov . 
For trials in which DMID is not the investigational new drug/investigational new device exemption (IND/IDE ) sponsor, or there is no IND/IDE, and DMID does not provide data 
management services, it is the responsibility of the investigator to register the tr ial and 
post results in compliance with Public Law 110-85, the Food and Drug Administration 
Amendments Act of 2007 (FDAAA).  
 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
47 of 49  
 17 LITERATURE REFERENCE S 
1. C enters for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 
2012. http://wwwcdcgov/std/stats12/Surv2012pdf  2012; accessed Aug 13, 2014. 
2. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending 
problem of resistance. Expert Opini on on Pharmacotherapy 2009 Mar; 1 0(4):555-77. 
[PMID: 19284360]  
3.  Echols RM , Heyd A , O'Keeffe BJ , Schacht P . Single-dose ciprofloxacin for the treatment 
of uncomplicated gonorrhea: a worldwide summary. Sex Transmitted D iseases.  1994 
Nov-Dec;21(6):345-52. [PMID: 7871449]  
4. Hook EW 3rd, Jones RB , Martin DH , Bolan GA , Mroczkowski TF , Neumann TM , Haag 
JJ, Echols R . Comparison of ci profloxacin and ceftriaxone as single-dose therapy for 
uncomplicated gonorrhea in women. Antimicrobial Agents and Chemotherapy. 1993 
Aug;37(8):1670-3. [PMID:8215281] 
5. C enters for Disease Control and Prevention. Cephalosporin susceptibility among 
Neisseria gonorrhoeae isolates , United States, 2000-2010. Morbidity and Mortality 
Weekly Report: 2011 Jul 8;60(26):873-7. [PMID: 21734634]  
6. Centers for Disease Control and Prevention. Update to CDC’s Sexually transmitted 
diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. Morbidity and Mortality Weekly Report 2012; Aug 
10; 61(31):590-4. [PMID: 22874837]  
7. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis  and Neisseria gonorrhoeae—2014. Morbidity and 
Mortality Weekly Report (MMWR). Recommendations and Reports. March 14, 2014/63(RR02);63:1-19. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6302a1.htm
 
8. Siedner MJ, Pandori M, et al. Real -time PCR assay for detection of quinolone-resistant 
Neisseria gonorrhoeae in urine samples. Journal of Clinical Microbiology 2007 Apr; 
45(4):1250-4. [PMID: 17267635]  
9.  Pandori M, Barry PM, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrobial Agents and 
Chemotherapy 2009 Sept; 53(9):4032-4. [PMID: 19546370]  
10.  Buono S, Wu A, Hess DC, Carlson JS, Rauch L, Philip SS, et al. Using the Neisseria 
gonorrhoeae multiantigen sequence-typing method to assess strain diversity and 
antibiotic resistance in San Francisco, California. Microbial Drug Resistance 2012 Oct; 
18(5): 510-7. [PMID: 22686196]  
11. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal 
infection. New England Journal of Medicine 2012 Feb 9; 366(6):485-7. [PMID: 
22316442].  
12. Kirkcaldy RD, Kidd S, Weinstock HS et al. Trends in antimicrobial resistance in Neisseria 
gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 
2006– June 2012. Sexually Transmitted Infections. 2013;89:suppl4:iv5–10. 
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
48 of 49  
 13. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. 
The effect of changes in the consumption of macrolide antibiotics on erythromycin 
resistance in group A streptococci in Finland: Finnish Study Group for Antimicrobial 
Resistance. New England Journal of Medicine 1997 Aug 14; 337(7):441-6. [PMID: 
9250845]  
14. Dicker LW, Mosure DJ, Steece R, Stone KM. Testing for sexually transmitted diseases in U.S. p ublic health laboratories in 2004. Sexually Transmitted Diseases 2007 Jan; 
34(1):41-6. [PMID: 16735955]  
15. Siedner MJ, Pandori M, Castro L, Barry P, Whittington WL, Liska S, Klausner JD. Real -
time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples. Journal of C linical  Microbiology 2007 Apr;45(4):1250-4. 
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimic robial 
Susceptibility Testing: 12th Informational Supplement. M100 -S1727], 124-2 5. 2007. Ref 
Type: Serial (Book, Monograph) 
17. Demczuk w, Lynch T, Martin I, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. Journal of Clinical Microbiology 2015; 53(1):191-200. 
18. Brown L, Cai T, DasGupta A. Interval estimation for a binomial proportion. Statistical 
Science 2001 16(2):101– 33. doi:10.1214/ss/1009213286  
19. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New England Journal of Medicine. 2004 Sep 16;351(12):1250-1. Epub 2004 Sep 8 
 
 
  
 DMID15 -0090 
 Version 7.0 
 17 December 2018  
 
 
 
 
  
 _____________________________________________________________________________________________  
 
 _____________________________________________________________________________________________  
49 of 49  
 APPENDIX A : SCHEDULE OF EVENTS 
Evaluation  Screening/  
Enrollment  
Visit 1  
Day 1  Visit 2  
Day 5-10 
(Test of 
Cure)  Visit 3  
Day 11- 143 
(Test of Cure 
Results)  Unscheduled/ 
Early  
Termination  
Visit5 
Signed consent form  X    
Confirmation of eligibility criteria  X    
Medical history f or assessment of specific symptoms that 
are potentially related to fluoroquinolone use as 
described in section 9, Assessment of Safety  X X  X 
Signs/symptoms  X X  X 
Concomitant medications  X X  X 
Sexual history  X    
Interim sexual history   X  X 
Targeted physical examination X X  X 
Rapid urine βhCG pregnancy test (females)  X    
Speculum examination (females)  X    
Cervical swab for N. gonorrhoeae  culture (females)  X2 X2   
Cervical or vaginal swab for NAAT  and gyrA assay  
(females)1 X2 X2   
Urethral swab for N. gonorrhoeae  culture (males)  X2 X2   
Urine specimen for NAAT  and gyrA assay  (males)1 X2 X2   
Throat swab for N. gonorrhoeae  culture and NAAT  and 
gyrA assay1 X2 X2   
Rectal swab for N. gonorrhoeae  culture and NAAT  and 
gyrA assay1 X2 X2   
Study intervention  X    
Reminder to abstain from sexual intercourse or use 
condoms  X   X5 
Reminder to bring partners in for treatment  X X X X 
Follow -up for test of cure results     X4  
1. GyrA  assay required only if NAAT is positive.  
2. Collect specimen at anatomic site of N. gonorrhoeae  infection .  
3. Follow -up for test of cure results  will be by phone call .  
4. For s ubjects N. gonorrhoeae  culture negative and NAAT negative, no further follow -up required.  
Subjects who are N. gonorrhoeae culture positive or NAAT positive will be referred for standard of care 
treatment for N. gonorrhoeae. 
5. Not required at the Early Termination Visit . 